Bundibugyo Ebola Vaccine: What's Being Developed

We've no approved shot. But research on the Bundibugyo Ebola vaccine is suddenly racing against a virus with no proven treatment as cases of this lesser-known strain climb across the Democratic Republic of the Congo and Uganda. So on Monday, the Coalition for Epidemic Preparedness Innovations awarded three developers a combined $60 million in emergency funding, signaling just how exposed the world feels.

Why This Outbreak Is Different

Most available Ebola tools target the Zaire strain, the bug behind the huge West African epidemic of 2014-16, but the current flare-up involves the Bundibugyo species, for which the cupboard is bare. Ervebo doesn't work against it. And that means health workers are once again relying on isolation, contact tracing, and supportive care while scientists sprint to close the gap.

There's a biological hurdle. But the security situation in eastern DRC is grim, with armed groups operating in affected zones, some Ebola treatment centres have been attacked, and tens of thousands are already displaced. Setting up drug trials in that landscape isn't merely difficult; it's dangerous. Yet the researchers we spoke with said they're ready to start the moment the environment allows.

The Vaccine Contenders

Three different candidates are now in development, each built on platforms that proved themselves during Covid‑19 or earlier Ebola outbreaks.

IAVI’s rVSV Candidate

It's the most promising option. But the IAVI vaccine rVSV Bundibugyo borrows the same vesicular stomatitis virus backbone that gave us Ervebo, and that familiarity is its strength but also a caution. The WHO expects clinical-trial doses won't be ready for seven to nine months.

He's pushing to beat it. Mark Feinberg, IAVI's president, points to a deeper failure that sounds almost personal after the 2014‑16 crisis, when loud calls to prepare, test, and stockpile vaccines against other Ebola strains never resulted in substantive action, and he said the technologies to make an efficacious Bundibugyo Ebola vaccine are available to us but we need to do the work to demonstrate that they do work.

Oxford’s ChAdOx1 Shot

It'll arrive faster. So Oxford University and the Serum Institute of India believe trials for the ChAdOx1 Bundibugyo Ebola vaccine could start in two or three months, not seven to nine. The partnership relies on the same chimpanzee adenovirus vector used in the Oxford/AstraZeneca Covid jab, a technology that'll scale with blistering speed to produce as many doses as the world needs.

But WHO experts want more animal data before giving the green light. Animal studies have started. Prof Teresa Lambe of the Oxford Vaccine Group confirmed that animal studies have already started with partners in both the UK and the US and they're moving quickly, adding, "I hope we won't ultimately need this vaccine but we're progressing as fast as we can.

Moderna’s mRNA Entry

Moderna's Bundibugyo Ebola vaccine missed the WHO shortlist because the company's response assessment wasn't finished when the expert panel met, and it uses the same messenger RNA platform that powered its Covid‑19 shot. But it's closing now. CEPI has committed up to $50 million of the emergency funding to support Moderna's preclinical development and early clinical testing. The company hopes to be ready for human trials within months. Stéphane Bancel, Moderna's chief executive, promised to "move with urgency and scientific rigour" to get a vaccine closer to the communities that need it most.

“Every day counts in the race against this deadly disease,” said Dr Richard Hatchett, chief executive of CEPI.

Treatments in the Pipeline

Vaccines are only one piece. Three existing medicines are being looked at as potential Bundibugyo treatments:

• MBP134 and Maftivimab, monoclonal antibodies that mimic the immune system’s own attack.
• Remdesivir, the antiviral that became a household name during Covid‑19.

The drugs exist. Amanda Rojek leads the Partners trial designed to pinpoint the most effective drug, and she's said investigators are "effectively close to ready to go." Teams are now seeking regulatory approval from authorities in both the DRC and Uganda. But the real hurdle is logistics. Working in a conflict zone means every step from transporting vials to monitoring patients must be operationalized safely. "We will implement the trial at a point at which patients are receiving optimised supportive care and we can manage the safety of our teams in a challenging environment," she said. She's stressed that in any outbreak, the only way to escape guesswork is rigorous evidence.

Blocking Infection Before It Starts

It's a first for Ebola. The antiviral drug obdeldesivir, given as a daily pill for ten days within 24 hours of exposure, provided up to 100% protection in monkeys against two other Ebola strains. And doctors will also test it as a prevention pill for contacts of confirmed cases, seeing if it stops them from developing the disease.

Prof Christophe Fraser of Oxford University, who will help run the trial, was blunt: if the drug is highly effective, the trial will deliver answers faster, but if it's modest, it takes longer. But the surveillance system's broken. He also said, "It also depends on the ability to follow up cases and find their contacts." At the moment, that's incredibly operationally challenging because of the security situation.

$60 million bought speed. But it's not certainty. The Bundibugyo Ebola vaccine frontrunners are each racing down different tracks, and the treatment trials will need peace as much as science, because for a disease that burns through bodies and communities the one thing nobody can afford is a trial that never starts.